On this page
Key takeaways
• Fisetin is a senolytic — it clears senescent cells (1). Resveratrol is a proposed sirtuin activator whose primary mechanism has been debated for two decades (2).
• Both have poor oral bioavailability. Resveratrol’s absorption is somewhat better on paper but its extensive first-pass metabolism to glucuronides and sulphates limits systemic exposure (7).
• Resveratrol has generated many human trials but mixed results. Some cardiometabolic RCTs are positive (3,4); many others are null. No consistent lifespan or healthspan endpoint has been demonstrated in humans.
• Fisetin has more focused senolytic evidence but pending human clinical validation. AFFIRM has been unreported since 2018 (9).
• Resveratrol has a well-characterised safety profile but a controversial history — celebrity backing, the Dipak Das research misconduct case (2012), and mixed trial replication.
• Combining fisetin and resveratrol is common in longevity practice and mechanistically distinct — no known interaction.
Quick answer
Fisetin and resveratrol are two of the most famous polyphenols in the longevity supplement world, but they have distinctly different mechanisms. Fisetin is a senolytic — it selectively clears senescent cells (1). Resveratrol was originally proposed as a sirtuin activator producing calorie-restriction-mimicking effects, though the mechanism has been contested since Baur’s 2006 Nature paper (2). Both have poor oral bioavailability. Resveratrol has more total human clinical trials but mixed results across cardiometabolic endpoints. Fisetin has focused senolytic preclinical evidence with human clinical validation still pending. If you must choose, the answer depends on what you are betting on: fisetin for the senolytic hypothesis, resveratrol for cardiometabolic and sirtuin-related effects. Combining them is defensible and common. For the fisetin context, see our complete clinician’s guide.
Chemistry and origin
Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonol — the same chemical subclass as quercetin. It is concentrated in strawberries and derived commercially from smoke tree extract.
Resveratrol (3,5,4′-trihydroxystilbene) is a stilbene — a distinct polyphenol class. It is concentrated in the skins of red grapes and Japanese knotweed root, from which it is commercially extracted. Resveratrol is the polyphenol at the centre of the "French paradox" hypothesis — the observation that moderate red wine consumption in French populations correlates with lower cardiovascular mortality despite a high-fat diet.
Both are polyphenolic antioxidants with anti-inflammatory activity. Both have poor oral bioavailability. Their differences lie in the specific downstream targets and the resulting therapeutic identities.
Different mechanisms — senolytic vs sirtuin activator
Fisetin — senolytic
Fisetin’s primary identity as a senolytic was established by the 2018 Yousefzadeh paper (1). It targets senescent cells through simultaneous interference with multiple SCAPs (BCL-xL, PI3K/AKT, kinases). See our dedicated senolytic article for the mechanism detail.
Resveratrol — sirtuin activator (contested)
Resveratrol’s original claim to fame was as a sirtuin activator — specifically, activating SIRT1 to produce effects mimicking calorie restriction. Baur’s 2006 Nature paper reported that high-dose resveratrol in high-fat-diet mice improved health and survival (2), and the mechanism was proposed to work through SIRT1 activation. This launched a decade of enthusiasm and multiple attempts to replicate the finding.
The direct-SIRT1-activation mechanism has since been extensively contested. Multiple groups have failed to replicate direct SIRT1 activation in vitro, and the sirtuin activation observed may be an artefact of assay conditions rather than a real biological effect. Alternative mechanisms have been proposed: AMPK activation via other pathways, adenosine receptor modulation, direct antioxidant activity, mitochondrial biogenesis via PGC-1α. The current honest picture is that resveratrol has genuine biological activity but that its "sirtuin activator" identity is oversimplified and possibly misleading.
Human clinical evidence — resveratrol’s history
Resveratrol has been extensively studied in human clinical trials — more so than fisetin — but with mixed and often disappointing results.
The positive trials
Timmers and colleagues (Cell Metab, 2011) randomised 11 obese men to 30 days of high-dose resveratrol vs placebo and reported improvements in energy metabolism, insulin sensitivity, and skeletal muscle mitochondrial function (3). Poulsen and colleagues (Diabetes, 2013) ran a similar trial in obese men and reported modest metabolic improvements (4). Some cardiovascular biomarker trials have shown small improvements in endothelial function and inflammation.
The null and negative trials
Many other resveratrol RCTs have failed to demonstrate meaningful clinical effects. A 2017 review of resveratrol clinical trials documented substantial heterogeneity in results across cardiometabolic, cognitive, and inflammatory endpoints, with meta-analyses generally finding small effects and considerable publication bias (8). The scale of the resveratrol clinical evidence is genuinely larger than the fisetin evidence, but the signal is not consistently positive.
The Dipak Das affair
In 2012 the University of Connecticut announced that Dipak Das, a prominent resveratrol researcher who had published extensively on its cardioprotective effects, had committed research misconduct across multiple papers. Twenty-six of his papers were retracted. This did not invalidate the broader resveratrol literature but it substantially undermined confidence in some of the specific mechanistic claims. It also illustrated a broader problem: the enormous commercial and public interest in resveratrol created incentives for both honest overreach and outright fraud.
Fisetin’s current human evidence
Fisetin’s human trials are more recent and more targeted — six ongoing or completed trials all using the pulsed senolytic protocol (9). The evidence is thinner but more focused. When AFFIRM publishes, the comparison changes. Until then, resveratrol has more total human data; fisetin has cleaner mechanistic focus.
Bioavailability comparison
Both compounds have poor oral bioavailability, but the mechanism differs. Fisetin is poorly absorbed due to low aqueous solubility (6). Resveratrol is somewhat better absorbed but undergoes extensive first-pass metabolism to glucuronides and sulphates, so systemic parent-compound concentrations remain low (7). Trans-resveratrol has an oral bioavailability of less than 1% by parent compound measurement.
Resveratrol’s response to formulation has been extensively studied — phytosome-based formulations (e.g., Resveratrol-Longevinex), liposomal formulations, and combination formulations with piperine or quercetin have shown modest bioavailability improvements. Fisetin’s formulation options are less commercially mature but include hydrogel and liposomal options. See our bioavailability article.
Dose and dosing
|
Aspect |
Fisetin |
Resveratrol |
|
Mechanism |
Senolytic |
Contested sirtuin activator; AMPK; mitochondrial biogenesis |
|
Typical daily dose |
100–500 mg (continuous) or 20 mg/kg pulsed |
250–1,500 mg daily continuous |
|
Bioavailability |
Poor absorption, low plasma peaks |
Better absorption but extensive first-pass metabolism |
|
Human RCT with clinical endpoint |
None yet published |
|
|
Safety profile |
Well tolerated in trials so far |
Well characterised, generally safe |
|
Cost per month |
Modest |
Modest to moderate |
When to choose which
For senolytic activity specifically: fisetin. Resveratrol does not primarily clear senescent cells and has no established senolytic mechanism.
For cardiometabolic endpoints: resveratrol has a longer trial history with some positive findings. If insulin sensitivity, endothelial function, or exercise-mimetic effects are your target, resveratrol has more direct evidence.
For established human trial evidence: resveratrol — more total trials, mixed but not empty results. Fisetin’s equivalent evidence base is thinner and pending.
For a mechanistically focused bet: fisetin. Its target is specific (senescent cells); its mechanism is well characterised. Resveratrol’s original sirtuin-activator identity is contested and its actual pharmacology in humans remains debated.
The stacking case
Combining fisetin and resveratrol is common in longevity practice. The mechanisms are distinct — no meaningful overlap, no documented negative interaction. Different metabolic pathways (resveratrol is primarily sulphated and glucuronidated; fisetin is methylated and conjugated). Both benefit from co-ingestion with fat. Practical stacking: resveratrol at 250–500 mg daily with breakfast; fisetin at either continuous 250–500 mg daily or pulsed 20 mg/kg × 2 days per month.
What we still don't know
• Whether resveratrol has any true SIRT1-independent longevity effect in humans. The mechanism debate is unresolved.
• Whether fisetin’s AFFIRM outcome, when it publishes, will meaningfully change the comparison by giving fisetin its first randomised human senolytic-outcome data.
• Whether combining fisetin and resveratrol produces additive human benefit. Not tested.
• Whether specific patient subgroups (metabolic syndrome, obesity, insulin resistance) benefit more from one or the other. Not directly compared.
Bottom line
Fisetin and resveratrol are two famous longevity polyphenols with distinctly different mechanisms and evidence bases. Resveratrol has more total human clinical trial data across cardiometabolic endpoints, but the results are mixed and the original sirtuin-activator mechanism is contested. Fisetin has focused preclinical senolytic evidence and pending human clinical validation. Both have poor oral bioavailability. If your goal is cardiometabolic support, resveratrol has more direct trial evidence. If your goal is targeted senolytic activity, fisetin is the more direct choice. Combining them is defensible and common. For the fisetin context, see our complete clinician’s guide.
Frequently asked questions
Is resveratrol still worth taking?
It has more human trial data than fisetin but mixed results. Whether it produces meaningful longevity benefits is unresolved. Reasonable to include in a longevity stack if cardiometabolic support is a goal; not a substitute for lifestyle interventions.
Can I take fisetin and resveratrol together?
Yes. No known interaction. Take together with a fat-containing meal.
Which has better human evidence?
Resveratrol has more total trials with mixed positive and null results across cardiometabolic endpoints. Fisetin has fewer trials with focused senolytic mechanistic evidence.
Is resveratrol dangerous?
No. It has a well-characterised safety profile at doses up to 1,500 mg/day in multiple trials (8). Very high doses can cause GI upset.
Should I get resveratrol from red wine?
No. The resveratrol content of red wine is roughly 1–2 mg per glass — far below supplement doses. Any benefit of moderate wine consumption is unlikely to be resveratrol-specific.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342. https://pubmed.ncbi.nlm.nih.gov/17086191/
3. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622. https://pubmed.ncbi.nlm.nih.gov/22055504/
4. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62(4):1186-1195. https://pubmed.ncbi.nlm.nih.gov/23193181/
5. Sarubbo F, Ramís MR, Kienzer C, et al. Chronic silymarin, quercetin and naringenin treatments increase monoamines synthesis and hippocampal Sirt1 levels improving cognition in aged rats. J Neuroimmune Pharmacol. 2018;13(1):24-38. https://pubmed.ncbi.nlm.nih.gov/28808887/
6. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
7. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9-15. https://pubmed.ncbi.nlm.nih.gov/21261636/
8. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1:35. https://pubmed.ncbi.nlm.nih.gov/29872711/
9. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037